Navigation Links
Emerging Data From Upsher-Smith's CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
Date:3/11/2013

MAPLE GROVE, Minn., March 11, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), is proud to sponsor emerging data for three investigational drug programs in epilepsy at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, CA, March 16-23, 2013.

Upsher-Smith's CNS pipeline consists of two Phase III programs: USL255 (topiramate), an investigational extended-release topiramate for the management of epilepsy in adults; and USL261 (midazolam) for the intranasal rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters.  Additionally, USL260 (tonabersat) is a potential first-in-class neuronal gap junction modulator in Phase I of development for treatment of epilepsy.

"Upsher-Smith is committed to improving the lives of people living with epilepsy by developing innovative treatments to address the unmet needs of those who suffer from this condition," said William Pullman, MB BS, BMedSc, PhD, FRACP, Chief Scientific Officer, Upsher-Smith.  "We are very pleased with the progress that has been made with each of our investigational CNS drug programs and are excited to share our ongoing scientific research in epilepsy at AAN's Annual Meeting."

Upsher-Smith sponsored posters include:

  • Single, High Doses of USL255, an Extended-Release Topiramate Formulation, Are Well Tolerated and Demonstrate a Dose-Proportional Pharmacokinetic Profile in Healthy Subjects
  • Poster 04.212; Session P04: Epilepsy: Antiepileptic Medications: Special Populations and Pharmacokinetics; Wednesday, March 20, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
  • Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration
  • P02.211; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
  • Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam
  • Poster 02.212; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
  • Tonabersat, a Novel Investigational Anti-Seizure Drug, Inhibits Seizures in Models of Generalized Epilepsy
  • Poster 02.209; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m. To schedule an interview with an investigator, please contact Elizabeth Likly at elikly@klcpr.com.  

    About Epilepsy
    Epilepsy is a medical condition that causes seizures affecting a variety of cognitive and physical functions.  More than two million people in the U.S. are estimated to be affected by epilepsy with about 200,000 new cases of epilepsy diagnosed each year.1

    About Upsher-Smith
    Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded, branded-generic and generic pharmaceuticals.  Upsher-Smith has a particular focus on providing therapies to assist people suffering from central nervous system diseases (including epilepsy, Parkinson's disease and Alzheimer's disease) and also markets products relating to cardiology, dermatology and women's health.  In addition to products currently marketed, Upsher-Smith has an emerging neurology pipeline with three products in clinical development, two of which are in Phase III clinical trials.  For more information, visit www.upsher-smith.com.

    References
    1. Epilepsy Foundation. About Epilepsy. Available at: http://www.epilepsyfoundation.org/aboutepilepsy/whatisepilepsy/statistics.cfm.  Accessed February 4, 2013.


    '/>"/>
    SOURCE Upsher-Smith Laboratories, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Innophos CFO To Present At 2013 Sidoti Emerging Growth Conference
    2. Frost & Sullivan Recognizes Cytomedix for its Pioneering System that Supports the Emerging Regenerative Therapies Market
    3. Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
    4. The 113th Canton Fair: "Great Opportunities for Emerging Markets"
    5. Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products
    6. Cumberland Emerging Technologies Expands Life Sciences Center
    7. Innovative CA Tumor Marker Tests Technologies and Emerging Markets
    8. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
    9. Innovative Hematology and Flow Cytometry Technologies and Emerging Markets
    10. Henry Schein Announces Featured Speakers For The "Recovery Empowerment Symposium: Emerging From The Storm"
    11. Cepheid Announces Executive Vice President Emerging Markets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
    (Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
    (Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
    (Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
    (Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
    (Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
    (Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
    Breaking Medicine News(10 mins):